ClinicalTrials.gg
Not yet recruitingNCT07353398Updated Mar 17, 2026

Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy

An Early Phase 1 interventional study of ART002g1 Injection in Heterozygous Familial Hypercholesterolemia, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.

Planned enrollment
18th of 22
24 · median 142
Started
2026
with 5 others
Phase 1
5 of 24
4 open now
Primary completion
2027-07
later than 6 of 12 live
Registered
18th of 24
by date

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 6 of the 12 other live ones, and was the 18th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, single ascending dose (SAD) study designed to evaluate the safety and tolerability of ART002g1 in patients with heterozygous familial hypercholesterolemia (HeFH) who require further reduction in low-density lipoprotein cholesterol (LDL-C). ART002g1 uses base editing technology, which is designed to interfere with the expression of the PCSK9 gene in the liver, thereby reducing the circulating levels of PCSK9 and LDL-C. The primary objectives of this study are to determine the safety and pharmacodynamic (PD) profiles of ART002g1 in this patient population.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia

Keywords

  • ART002g1
  • LNP
  • HeFH
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all the following criteria to be eligible for enrollment:

  1. Male or female, aged 18 to 70 years (inclusive) at the time of signing the Form (ICF);
  2. Body weight between 45 and 90 kg (inclusive) at screening;
  3. Definite diagnosis of heterozygous familial hypercholesterolemia (HeFH), meeting either of the following two criteria (1) or (2):

(1) HeFH diagnosed to be caused by mutations in the LDLR, APOB, or PCSK9 gene;

(2) Meeting 2 out of the 3 following criteria for adults per the Dutch Lipid Clinical Network (DLCN) criteria:

  1. Serum LDL-C ≥ 4.7 mmol/L without prior lipid-lowering treatment;
  2. Cutaneous or tendinous xanthomas, or arcus cornealis (in subjects \< 45 years old);
  3. Presence of FH or early-onset atherosclerotic cardiovascular disease (ASCVD) in first-degree relatives.

Subjects must not be enrolled if they meet any one or more of the following exclusion criteria:

  1. Diagnosis of compound heterozygous FH, double heterozygous FH, or homozygous FH (HoFH);
  2. Positive for surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer ≥ 1 × 10² copies/L; positive for virus (HCV) antibody with positive peripheral blood HCV RNA; positive for (HIV) antibody;
  3. Any unstable systemic disease, including but not limited to: unstable angina; cerebrovascular accident or (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening); history of heart failure ( Class II-IV); severe arrhythmia requiring pharmacotherapy; liver, kidney, or metabolic diseases; or other unstable systemic diseases as determined by the investigator;
  4. History of percutaneous transluminal coronary angioplasty (PTCA), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 6 months prior to the first dose; or documented severe coronary artery stenosis as confirmed by coronary CT or coronary angiography within 90 days prior to randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Experimental: ART002g1 Injection - Dose Group 1 ( Single IV Infusion)

    Participants will receive a single dose of ART002g1.

    Drug: ART002g1 Injection

  • Experimental
    Experimental: ART002g1 Injection - Dose Group 2 (Single IV Infusion)

    Participants will receive a single dose of ART002g1.

    Drug: ART002g1 Injection

  • Experimental
    Experimental: ART002g1 Injection - Extended Dose Group ( Single IV Infusion)

    Participants will receive a single Optimal Biological Dose (OBD) of ART002g1, which is based on the results of the ascending dose escalation.

    Drug: ART002g1 Injection

Interventions

  • DrugART002g1 Injection

    Intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection

Secondary outcomes

  1. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Tmax

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  2. Pharmacodynamic (PD) Assessments: Serum PCSK9 protein

    Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection

  3. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Cmax

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  4. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: AUC

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  5. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: t½

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  6. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: CL

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  7. Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1:Vss

    Time frame: As of Week 2 (W2) post-administration of ART002g1 for Injection

  8. Pharmacodynamic (PD) Assessments: Serum LDL-C

    Time frame: As of Week 48 (W48) post-administration of ART002g1 for Injection

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Jul 2027, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 20, 2026
StartEst.
Mar 11, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07353398
Collaborators
Accuredit Therapeutics US Limited
Responsible party
Rong Jiang (Associate Chief Physician, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Jan 20, 2026
Start date
Mar 11, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Xueying Ding, MD
Contact
dingxueying@126.com
+86-02136126102
Rong Jiang, MD
Contact
listening39@163.com
+86 13795493921
Xueying Ding, MD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Rong Jiang, MD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion